Nardil announcement

March 18th 2020

ERFA Canada 2012 Inc. is presently in backorder for the product Nardil

(phenelzine sulphate) DIN 00476552.

Description of product affected:

NARDIL (phenelzine sulfate) is indicated in the treatment of depressed patients clinically characterized as “atypical”, “nonendogenous” or “neurotic”. These patients often have mixed anxiety and depression and phobic or hypochondriacal features. NARDIL is indicated for patients who have failed to respond to the drugs more commonly used for these conditions.1,2

Phenelzine is also used in patients with anxiety, post-traumatic stress disorder and panic disorder.3

The backorder is due to a global shortage of the active ingredient.

The earliest availability date of the product is expected at the end of May 2020.

If there is potential for patients maintained on Nardil to run out of supply during this shortage, they should be urgently referred back to mental health specialist for advice on ongoing clinical management.

We are truly sorry about the inconvenience.

Please be sure we are working hard to make Nardil available as soon as possible.

We will come back to you as soon as we will have news.

Yours truly,

1. ERFA Canada 2012 Inc. Nardil. Product Monograph.Dec 2015.

2. Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. pharmacological Treatments Can J Psychiatry. 2016;61(9):540–560.

3. Katzman, M.A., Bleau, P., Blier, P. et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry 14, S1 (2014).